G2PR experience spans population sizes and therapy areas

Rare diseases

Including ultra-orphan conditions

Specialty therapies

Tertiary, secondary, and community care

Population health

Prevention (vaccines, therapies) and primary care

G2PR can confidently cover your therapy areas

Therapy area highlights, non-exhaustive, being added to with every project

Oncology - solid & haematological

NSCLC, mesothelioma, leukaemia, oncolytic viruses, cell therapies

Inflammation & immunology

Psoriatic arthritis, systemic sclerosis, interstitial pulmonary fibrosis

Haematology

Plasma-derived therapies, recombinant therapies, thrombocytopenia

Metabolic

Diabetes - types 1 & 2, obesity, rare genetic conditions

Cardiovascular

Stroke, myocardial infarction, pulmonary embolism, heart failure, hyperlipidaemias

Renal

Hypertension, overactive bladder, chronic kidney diseases, renal failure

Dermatology

Psoriasis, scleroderma, raynaud’s

Neurology

Epilepsy, depression, schizophrenia

Ophthalmology

Glaucoma, macular degeneration

Endocrinology

Women’s & men’s health

Respiratory

Asthma, COPD, fibrosis

Vaccines & anti-infectives

Prevention & therapies, COVID

Devices

Aortic aneurysms, CABG, insulin pumps

Software

Making sense of data, AI in healthcare

G2PR experience breadth is global, with local depth

Health and wellbeing belongs to all of us

Established and growing global and local geographical spread of impact

US, Canada

25%

UK, Republic of Ireland

25%

Europe

25%

Asia-Pacific, South America

25%

G2PR can offer you a variety of support

Growing selection of project archetypes

  • Evidence generation plan

    Evidence gap identification & filling

    Publication & dissemination plan & execution

  • Global price guidance

    Indication sequencing

    Negotiation preparation

  • Early-stage modelling

    Affordability (budget-impact)

    Value-for-money (cost-benefit)

  • Healthcare resource utilisation

    Burden-of disease, patient pathway

    Literature reviews - systematic, comprehensive

  • Evidence synthesis

    Evidence generation plan fitness

    Evidence generation plan creation

  • Publication plans

    Formulary applications

    Health technology appraisal dossiers (NICE, SMC, etc.)

  • Global equitable medicines access policy

    Early access to medicines scheme set-up

    Appraisal process and method engagement

  • Health systems (NHS, HSE)

    Advisory board preparation & facilitation

    Health technology assessment bodies (NICE, SMC, NCPE)

  • Impact maximisation

    Resource optimisation

    Prescriber & payer engagement

  • Innovation launch

    Health-system uptake

    Re-launch, even post-patent-expiry

Workflow coordination

  • Access

    Medical

    Commercial

  • Individuals

    Large vendors

    Partnership approach

  • Other vendors

    Publication readiness

    Submission readiness

Underpinned by core strengths

  • Engagement

    Collaboration

    Genuine alignment

  • Training

    Innovation

    Skills sustainability

  • Compliant

    Your values

    G2PR values